Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  9.00 0.57% 1,600.80 1,600.00 1,600.80 1,602.00 1,597.40 1,597.40 156,657 08:02:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.0 6,221.0 93.9 17.0 80,537

GlaxoSmithKline, Vir Biotechnology to Supply Covid-19 Treatment to European Commission

28/07/2021 12:18pm

Dow Jones News

Glaxosmithkline (LSE:GSK)
Historical Stock Chart

From Jun 2021 to Dec 2021

Click Here for more Glaxosmithkline Charts.

By Chris Wack


GlaxoSmithKline PLC and Vir Biotechnology Inc. said they have signed a joint procurement agreement with the European Commission to supply up to 220,000 doses of Covid-19 treatment sotrovimab.

The companies said sotrovimab is an investigational single-dose SARS-CoV-2 monoclonal antibody for the treatment of adults and adolescents with Covid-19 who don't require oxygen supplementation and who are at risk of progressing to severe Covid-19.

The agreement enables participating European Union member states to quickly purchase sotrovimab, following local emergency authorization or authorization at the EU level, to treat high-risk patients with Covid-19 who may benefit from early treatment with the medication, the companies said.

Sotrovimab is included in the European Commission's portfolio of promising candidate therapies as part of its Covid-19 Therapeutics Strategy.

Glaxo and Vir have secured supply agreements with a number of governments around the world and will continue those efforts as the pandemic continues to evolve, the companies said. In May, sotrovimab was granted emergency-use authorization by the U.S. Food and Drug Administration for the treatment of mild-to-moderate Covid-19 in high-risk patients. Glaxo and Vir plan to submit a biologics license application to the U.S. FDA in the second half of 2021.


Write to Chris Wack at chris.wack@wsj.com


(END) Dow Jones Newswires

July 28, 2021 07:05 ET (11:05 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Glaxosmithkline Chart

1 Year Glaxosmithkline Chart

1 Month Glaxosmithkline Chart

1 Month Glaxosmithkline Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20211209 08:17:27